Applied DNA Reports First Quarter Fiscal 2023 Financial Results
- Total Revenues of $5.3 Million, Up 48% Over FQ4 2022 and 26% Over FQ1 2022, 72% and 74% Reduction in Operating Loss, Respectively -- Included Orders for R&D Quantities of linearDNA™ from New Biopharma Customers -- Maintains Timeline to cGMP Capacity, Initiates Build-out of Cost-Efficient Facility -- Business Updat...
Source: pharmiweb.com
